ACAD · Company research
Acadia Pharmaceuticals Inc. (ACAD): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance | ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK | ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada | Acadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? | Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? | Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits | ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Acadia Pharmaceuticals (NasdaqGS:ACAD) Stock Forecast & Analyst Predictions - Simply Wall Street | Acadia Pharmaceuticals (NasdaqGS:ACAD) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada | ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance | ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - Yahoo Finance Singapore | Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 7, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Yahoo Finance | Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss - Trefis | Acadia Pharmaceuticals Stock Extends A 7-Day Losing Streak To A 25% Loss Trefis | View source ↗ | Trefis | Oct 2, 2026 | neutral | 0 | 0.6 |
| A dosing patent could add nearly five years of U.S. protection for a Rett syndrome treatment - Stock Titan | A dosing patent could add nearly five years of U.S. protection for a Rett syndrome treatment Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance | Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop Yahoo Finance | View source ↗ | Yahoo Finance | Sep 27, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - Simply Wall Street | Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push Simply Wall Street | View source ↗ | Simply Wall Street | Sep 26, 2026 | neutral | 0 | 0.6 |
| ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - TradingView | ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal TradingView | View source ↗ | TradingView | Sep 25, 2026 | neutral | 0 | 0.6 |
| ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets - TradingView | ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets TradingView | View source ↗ | TradingView | Sep 25, 2026 | neutral | 0 | 0.6 |
| ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets - Yahoo Finance | ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - Yahoo Finance | ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| $ACAD stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $ACAD stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 24, 2026 | neutral | 0 | 0.6 |
| $ACAD stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $ACAD stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 24, 2026 | neutral | 0 | 0.6 |
| Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth - Yahoo Finance | Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth Yahoo Finance | View source ↗ | Yahoo Finance | Aug 7, 2026 | neutral | 0 | 0.6 |
| ACADIA Pharmaceuticals (ACAD) Stock Still Looks Below Fair Value Despite Clinical Risk - Yahoo Finance | ACADIA Pharmaceuticals (ACAD) Stock Still Looks Below Fair Value Despite Clinical Risk Yahoo Finance | View source ↗ | Yahoo Finance | Jul 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.